Merck says once-daily HIV drug combo succeeds in another Phase 3news2025-11-19T14:51:35+00:00November 19th, 2025|Endpoints News|
New report suggests America must wean off China APIsnews2025-11-18T20:37:33+00:00November 18th, 2025|Endpoints News|
Senator questions Lilly CEO on details of Trump deal for weight loss drugsnews2025-11-18T20:16:32+00:00November 18th, 2025|Endpoints News|
Arrowhead gets FDA approval for rare lipid disease drugnews2025-11-18T18:52:23+00:00November 18th, 2025|Endpoints News|
Drugmakers say HHS’ 340B pilot is limited as they fight for their own rebate modelsnews2025-11-17T21:00:33+00:00November 17th, 2025|Endpoints News|
Zymeworks and Jazz tout HER2 bispecific success in first Phase 3 readoutnews2025-11-17T20:44:06+00:00November 17th, 2025|Endpoints News|
New US trade deal caps Switzerland, Liechtenstein pharma tariffs at 15%news2025-11-17T19:14:06+00:00November 17th, 2025|Endpoints News|
Novo Nordisk lowers self-pay prices for weight loss drugs ahead of Lilly, TrumpRxnews2025-11-17T18:22:42+00:00November 17th, 2025|Endpoints News|
Scholar Rock plans to launch spinal muscular atrophy drug next yearnews2025-11-17T17:48:23+00:00November 17th, 2025|Endpoints News|
Merck is still hunting for deals after two major bolt-on acquisitions this yearnews2025-11-17T15:58:32+00:00November 17th, 2025|Endpoints News|
